MSD Wins NMPA Approval for Keytruda-Lenvima Combo in Hepatocellular Carcinoma
US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) announced that China’s National Medical Products Administration...
NYSE: MRK
Merck Launches Phase III Trial for Quadrivalent Dengue Vaccine V181
US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) announced the launch of the Phase III...
FDA Approves Merck’s Enflonsia for Infant RSV Protection
The US Food and Drug Administration (FDA) granted approval to Merck, Sharp & Dohme’s (MSD;...
MSD Presents Zilovertamab Vedotin Results at ASCO Annual Meeting
US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) last week presented results from the dose...
MSD Appoints Kyle Tattle as President of China Operations
US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) announced leadership changes in its China and...
MSD and Daiichi Sankyo Withdraw US Filing for Patritumab Deruxtecan in EGFR-Mutated NSCLC
Partners Merck, Sharp & Dohme (MSD; NYSE: MRK) and Daiichi Sankyo (TYO: 4568) announced the...
Merck’s Welireg Launched in China for Rare Genetic Disorder Treatment
US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) announced the commercial launch of its hypoxia-inducible...
Antengene and MSD Collaborate on ATG-022 for Advanced Solid Tumors
China-based Antengene Corporation Limited (HKG: 6996) has entered into a collaboration with US major Merck,...
Merck Sharp & Dohme Initiates Phase III Trial of Ifinatamab Deruxtecan for Esophageal Cancer
US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) announced the first patient dosing in...
Merck’s Keytruda Meets Primary Endpoint in Phase III Ovarian Cancer Trial
US-based Merck Sharp & Dohme Inc. (MSD; NYSE: MRK) announced positive results from the Phase...
FDA Approves Merck’s Welireg for Locally Advanced or Metastatic Pheochromocytoma and Paraganglioma
The US Food and Drug Administration (FDA) announced this week an indication extension approval for...
Merck Sharp & Dohme Launches Recarbrio in China for Bacterial Pneumonia and Infections
US-based pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced the official...
Merck Sharp & Dohme Announces $1 Billion Biologics Center in Wilmington, Delaware
US-based pharmaceutical giant Merck, Sharp & Dohme (MSD, NYSE: MRK) has announced the establishment of...
Merck Q1 2025 Results: Keytruda Sales Grow 6% Despite Gardasil Dip in China
Global pharmaceutical company Merck (NYSE: MRK) released its Q1 2025 financial results, showing total sales...
Cyprumed Signs Non-Exclusive License Agreement with MSD for Oral Peptide Delivery Tech
Germany-based Cyprumed GmbH has entered into a non-exclusive license and option agreement with Merck, Sharp...
MSD’s Gardasil 9 Approved in China for Males Aged 16 to 26
US pharmaceutical major Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced marketing approval from...
Merck, Sharp & Dohme’s Capvaxive Approved by European Commission for Pneumococcal Prevention
US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced the European Commission (EC)...
Jiangsu Hengrui Pharmaceuticals Inks Global License Deal with Merck for HRS-5346
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced a license agreement with US-based giant Merck...
Sichuan Kelun-Biotech Reports 25.5% Revenue Growth with Key Drug Approvals
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has released its 2024 financial report, recording...
Merck & Co.’s Winrevair Approved for Pulmonary Arterial Hypertension in Hainan
US-based giant Merck & Co., Inc. (NYSE: MRK) announced receiving approval from the Hainan Medical...